The burden of HCV treatment in patients with inherited bleeding disorders

Haemophilia

Volumn 17, Issue 5, 2011, Pages 791-799

  Fransen Van De Putte, D E ^a   Fischer, K ^a,b   Posthouwer, D ^a,b   Mauser Bunschoten, E P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antiviral treatment; Haemophilia; Hepatitis C; Side effects

Indexed keywords

ANTIVIRUS AGENT; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AMNESIA; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BECK DEPRESSION INVENTORY; BLEEDING DISORDER; CLINICAL ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRY EYE; DYSPNEA; EYE PAIN; FATIGUE; FEMALE; FOLLOW UP; HAIR LOSS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRRITABILITY; LEUKOCYTE COUNT; LEUKOPENIA; MALE; NAUSEA; OTALGIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SIDE EFFECT; SLEEP DISORDER; SORE THROAT; TASTE PREFERENCE; THIRST; THROMBOCYTE COUNT; THROMBOCYTOPENIA; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BLOOD COAGULATION DISORDERS, INHERITED; COST OF ILLNESS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RIBAVIRIN; YOUNG ADULT;

EID: 80052034156     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02602.x     Document Type: Article

References (35)

1. Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP. Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia 2005; 11: 270-5.
2. Posthouwer D, Makris M, Yee TT et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109: 3667-71.
3. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
5. Morgan TR, Ghany MG, Kim HY et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
6. Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
7. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
8. Denholm JT, Wright EJ, Street A, Sasadeusz JJ. HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection. Haemophilia 2009; 15: 538-43.
9. Katsarou O, Theodosiades G, Ioannidou P et al. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders. Acta Haematol 2008; 120: 63-9.
10. Mancuso ME, Rumi MG, Santagostino E et al. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica 2006; 91: 1367-71.
11. Mancuso ME, Rumi MG, Aghemo A et al. Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy. J Thromb Haemost 2009; 7: 1997-2005.
12. Maor Y, Schapiro JM, Bashari D et al. Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience. Haemophilia 2008; 14: 336-42.
13. Posthouwer D, Fischer K, De Heusden N, Mauser-Bunschoten EP. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: a single-centre experience. Haemophilia 2007; 13: 98-103.
14. Alavian SM, Tabatabaei SV, Keshvari M et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int 2010; 30: 1173-80.
15. Fransen van de Putte DE, Fischer K, Post-houwer D, van Erpecum KJ, Mauser-Bunschoten EP. Occurrence, course and risk factors of depression during antiviral treatment for chronic hepatitis C in patients with inherited bleeding disorders: a prospective study. Haemophilia 2009; 15: 544-51.
16. Beck AT, Steer RA. Manual for the Beck Depression Inventory I-A. San Antonio, TX: Psychological Corporation, 1993.
17. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993; 2: 217-27.
18. Van der Zee KI, Sanderman R. Measuring General Health with the RAND-36 Questionnaire - A Guideline. Groningen, The Netherlands: Noordelijk Centrum voor Gezondheidsvraagstukken, 1993.
19. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001; 33: 350-7.
20. Gheorghe L, Iacob S, Sporea I et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007; 16: 23-9.
21. Raison CL, Borisov AS, Broadwell SD et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41-8.
22. Loftis JM, Socherman RE, Howell CD et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004; 365: 87-91.
23. Suwantarat N, Tice AD, Khawcharoenporn T, Chow DC. Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment. Int J Med Sci 2010; 7: 36-42.
24. Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999; 5: 378-85.
25. Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP. Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica 2005; 90: 846-50.
26. Strauss E, Teixeira MCD. Quality of life in hepatitis C. Liver Int 2006; 26: 755-65.
27. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007; 45: 806-16.
28. Hassanein T, Cooksley G, Sulkowski M et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004; 40: 675-81.
29. Dan AA, Martin LM, Crone C et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491-8.
30. Kang SC, Hwang SJ, Lee SH, Chang FY, Lee SD. Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol 2005; 11: 7494-8.
31. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-8.
32. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82: 175-90.
33. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207-11.
34. McHutchison JG, Everson GT, Gordon SC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
35. McHutchison JG, Manns MP, Muir AJ et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.